EXAI - Exscientia Collaborates with Merck KGaA for AI Drug Discovery Program

2023-09-20 08:32:17 ET

(24/7 MARKET NEWS) – Exscientia plc (NASDAQ:EXAI) introduced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology, utilizing Exscientia’s AI-driven precision drug design and discovery capabilities while leveraging Merck KGaA’s disease expertise in oncology and neuroinflammation, clinical development capabilities and global footprint.

Exscientia is eligible to receive up to $674 million in discovery, development, regulatory and sales-based milestones for three projects, in addition to single to double digit royalty payments on net sales, as well as up to $113 million in potential milestone payments in the discovery phase, with $20 million upfront at initiation for three projects.

Exscientia is trading at $$6.45, up $1.39 (+27.47%), on …

The post Exscientia Collaborates with Merck KGaA for AI Drug Discovery Program appeared first on 24/7 Market News .

For further details see: